Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 163 results for copd

  1. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

    Medtech innovation briefing
    Published
    5 June 2018

  2. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations? Any...

    Research recommendation
    Published
    13 February 2019

  3. Non-Invasive Ventilation – Improving patient experience and outcomes through understanding (INTU)

    Approximately 3 million people in the UK have COPD which is the fifth leading cause of death. Type 2 respiratory failure occurs

    Shared learning
    Last updated
    14 November 2019

  4. Smoking: support and treatment for people with long term conditions (IND157)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM127

    General practice indicators suitable for use in QOF
    Last updated
    27 August 2021

  5. Weight management: BMI recording (long-term conditions) (IND151)

    This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, hypertension, peripheral arterial disease, heart failure, COPD, asthma and/or rheumatoid arthritis who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM121

    General practice indicators suitable for use in QOF
    Last updated
    8 September 2022

  6. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  7. Smoking: support and treatment for people with long-term conditions or SMI (IND98)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM39

    General practice indicators suitable for use in QOF
    Last updated
    26 November 2021

  8. Evidence on the safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in quantity. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page. Further research should be randomised controlled trials comparing the procedure with sham treatment. It should report details of patient selection, and short and long-term functional outcomes including lung functional outcomes, quality of life and patient-reported outcomes, incidence of exacerbations and hospital admissions, and all adverse events.

    safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in...

    Research recommendation
    Published
    7 January 2022

  9. To develop new partnerships to achieve best practice in End of Life Care (EOLC) through the provision of education programmes

    specific EOL challenges e.g. palliative management in Chronic Obstructive Pulmonary Disease (COPD). Providing a conference...

    Shared learning
    Last updated
    20 February 2018

  10. Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation during hospital admission for exacerbation and/or in the early recovery period (within 1 month of an exacerbation) improve quality of life and reduce hospitalisations and exacerbations compared with a later (defined as after 1 month)pulmonary rehabilitation programme, and in which groups is it most clinically and cost effective?

    Question Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation during hospital...

    Research recommendation
    Published
    6 February 2019

  11. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  12. Bronchoscopic intrabullous autologous blood instillation (BIABI) for the therapy of Emphysema: intractable with pneumothorax, COPD & Lung cancer, patients requiring lung biopsy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  13. Insertion of endobronchial nitinol coils to improve lung function in emphysema (IPG517)

    Evidence-based recommendations on insertion of endobronchial nitinol coils to improve lung function in emphysema. This involves inserting coils to reduce airflow to damaged parts of the lung.

    Interventional procedures guidance
    Published
    27 March 2015
    View recommendations

    Sections for IPG517

  14. Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

    Medtech innovation briefing
    Published
    14 September 2016